ECSP961693A - ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE - Google Patents

ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE

Info

Publication number
ECSP961693A
ECSP961693A ECSP961693A ECSP961693A EC SP961693 A ECSP961693 A EC SP961693A EC SP961693 A ECSP961693 A EC SP961693A EC SP961693 A ECSP961693 A EC SP961693A
Authority
EC
Ecuador
Prior art keywords
oral formulation
cellulose
hypromellose
benzodiaceptine
theno
Prior art date
Application number
Other languages
Spanish (es)
Inventor
George Randall Cochran
Tommy Clifford Morris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP961693 priority Critical patent/ECSP961693A/en
Publication of ECSP961693A publication Critical patent/ECSP961693A/en

Links

Abstract

El invento se refiere a una formulación oral sólida que comprende alanzapina como ingrediente activo, mezclada intimamanete con un agente de carga; aglutinante, disgregante, un aglutinante seco para proporcionar fiabilidad adecuada, y un lubricante; en la que dicha formulación oral sólida está recubierta con un polímero seleccionado entre el grupo formado por hidroxipopil hipromelosa, hidroxietil celulosa, metilhidroxietil celulosa, carboxihipromelosa de sodio, hidroxipropil celulosa, polivinilpirrolidona, copolímero del éster dimetilaminoetílico metacrilato-éster dimetilaminoetílico metilacrilato, copolímero de etilacrilato-metilmetacrilato, hipromelosa y etilcelulosa.The invention relates to a solid oral formulation comprising alanzapine as an active ingredient, intimately mixed with a bulking agent; binder, disintegrant, a dry binder to provide adequate reliability, and a lubricant; wherein said solid oral formulation is coated with a polymer selected from the group consisting of hydroxypropyl hypromellose, hydroxyethyl cellulose, methylhydroxyethyl cellulose, sodium carboxypromellose, hydroxypropyl cellulose, polyvinylpyrrolidone, dimethylaminoethyl methacrylatyl-ethyl acrylate ester copolymer methyl methacrylate, hypromellose and ethyl cellulose.

ECSP961693 1996-03-21 1996-03-21 ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE ECSP961693A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP961693 ECSP961693A (en) 1996-03-21 1996-03-21 ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP961693 ECSP961693A (en) 1996-03-21 1996-03-21 ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE

Publications (1)

Publication Number Publication Date
ECSP961693A true ECSP961693A (en) 1997-09-22

Family

ID=42042425

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP961693 ECSP961693A (en) 1996-03-21 1996-03-21 ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE

Country Status (1)

Country Link
EC (1) ECSP961693A (en)

Similar Documents

Publication Publication Date Title
CO4700474A1 (en) ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE
ES8200557A1 (en) Sustained release pharmaceutical composition of solid medical material
AR049055A2 (en) A QUICKLY REMOVABLE TABLET FOR ORAL ROUTE ADMINISTRATION
NO20011471D0 (en) New oral sustained release formulations
FI962111A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
ES2159591T3 (en) COMPOSITION OF CONTROLLED RELEASE.
UA94917C2 (en) Topical formulations
DK1276470T3 (en) Flavor-crushing coating composition
KR970025607A (en) Sustained Release Nifedipine Formulation
PT1183014E (en) ORAL PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED LIBERATION AND TISSUE DISSIMULATION
ECSP055748A (en) CONTROLLED RELEASE COMPOSITIONS
AR022672A1 (en) A PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS OR CAPSULES THAT CONSTITUTE AN ORAL ADMINISTRATION METHOD OF A DRUG
ATE391495T1 (en) MATRIX SYSTEM WITH DELAYED RELEASE FOR HIGHLY SOLUBLE ACTIVE INGREDIENTS
DE60023107D1 (en) PREPARATIONS WITH IMPROVED CONTROLLED RELEASE
PT1318792E (en) PROLONGED LIBERATION COMPOSITION CONTAINING CLARITHROMYCIN
ES2196620T3 (en) FORMULATION OF PROLONGED RELEASE CONTAINING VENLAFAXINE.
AR021578A1 (en) FORMULATION IN PRAVASTATIN PEARLS WITH ENTERIC COATING
EA200001201A2 (en) Matrix tablet for prolonged release of trimetazidine
NO20055601L (en) Pharmaceutical preparation in the form of a hydrogel for transdermal administration of active ingredients
RS50298B (en) Directly compressibile matrix for controlled release of single daily doses of clarithromycin
AR021934A1 (en) COMPOSITION OF ORAL ADMINISTRATION WITH CONTROLLED RELEASE OF AT LEAST ONE ANALGESIC
AU2697100A (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
ECSP961693A (en) ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE
TR200200683T2 (en) Oral controlled release formulations.
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.